Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023

ROCKWELL MEDICAL, INC.

2023-Q3 EPS reported -$0.32 revenue$61,519,000

Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.
Operating loss $1.7M, improved 53% YoY; net loss $1.9M vs $4.2M in Q3 2022.
2023 guidance reaffirmed: net sales $82-86M (+17-18% YoY), gross profit $8-10M (+95-144% YoY).
Company now expects adjusted EBITDA profitability in Q4 2023, ahead of prior 2024 target.
Acquired Evoqua hemodialysis concentrates assets; became leading US supplier of liquid bicarbonate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKWELL MEDICAL, INC. reported the three months ended September 30, 2023 results: revenue $23.8 million. Guidance reaffirmed.

Period: the three months ended September 30, 2023
Revenue: $23.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

99.1) --- EX-99.1 2 tm2330647d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces Third Quarter 2023 Results · Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. · Gross profit for the third quarter of 2023

View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-117573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.